Compounds and compositions for treating conditions associated with NLRP activity

Patent metadata

Field	Value
Publication number	US-12084424-B2
Application number	US-202318319630-A
Country	US
Kind code	B2
Filing date	May 18, 2023
Priority date	Jul 24, 2017
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:

or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

First claim

We claim:

1. A compound selected from the group consisting of:

wherein TBS is tert-butyldimethylsilyl and Boc is tert-butyloxy carbonyl, and pharmaceutically acceptable salts thereof.

2. The compound of claim 1 , selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

3. The compound of claim 1 , selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

Assignees

• Novartis Ag

Inventors

• Franchi Luigi
• Ghosh Shomir
• Glick Gary
• Katz Jason
• Opipari Jr Anthony William
• Roush William
• Seidel Hans Martin
• Shen Dong-Ming
• Venkatraman Shankar
• Winkler David Guenther

Classifications

• C07D487/04

  Ortho-condensed systems · CPC title

• C07D317/62

  with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring · CPC title

• C07D307/79

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring · CPC title

• C07D263/46

  Sulfur atoms · CPC title

• C07D239/26

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title